Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial [version 2; peer review: 2 approved]

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial [version 2; peer review: 2 approved]

Background: Prostate cancer is the most commonly diagnosed malignancy in the UK. Castrate resistant prostate cancer (CRPC) can be difficult to manage with response to next generation hormonal treatment variable. AR-V7 is a protein biomarker that can be used to predict response to treatment and poten...

Full description

Bibliographic Details
Main Authors: Rebecca Maier, Aislinn Cooper, Robert Chandler, John Marshall, Simon Crabb, Amit Bahl, Ian Pedley, Suneil Jain, John Staffurth, Rob Jones, Rakesh Heer, Paul Gravestock, Miranda Morton, Emma Clark, Holly Fisher, Shirya Sharma, Ruth Wood, Jenn Walker, Nichola Waugh, Helen Hancock
Format: Article
Language:English
Published: F1000 Research Ltd 2023-01-01
Series:NIHR Open Research
Subjects:
prostatic neoplasms
castration-resistant
biomarkers
feasibility studies
male
eng
Online Access:https://openresearch.nihr.ac.uk/articles/2-49/v2

Internet

https://openresearch.nihr.ac.uk/articles/2-49/v2

Similar Items